|View printer-friendly version|
|FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis|
There are currently no
“This is an extremely exciting moment as we expand BrainStorm’s pipeline by introducing a new indication for NurOwn® in neurodegenerative disease,” said
MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide. Approximately half of affected individuals will eventually develop progressive disease, which may lead to increasing levels of motor, visual, and cognitive functional impairment and disability.
“We are excited about the launch of early testing of this cell-based approach to treating progressive MS, for which there are few treatment options,” commented
“We are excited to participate in this Phase 2 clinical trial and hope that this innovative cell therapy approach leads to a new treatment option for patients with progressive MS,” said Dr.
About BrainStorm Cell Therapeutics Inc.